EDGEMOND JAMES sold $1.1M of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 1,961 shares of UNITED THERAPEUTICS Corp (UTHR) at $562.77 ($1.10M total) on 2026-05-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the sale is explicitly under a pre-arranged Rule 10b5-1 plan, it is generally treated as non-informational for near-term fundamental repricing.
Market read
A disclosed insider sale can slightly influence sentiment, but the 10b5-1 designation makes it unlikely to be a fresh catalyst.
What to watch
The filing does not disclose motivations (tax, diversification, liquidity needs), and the share count is small relative to typical large-cap float.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
United Therapeutics CFO and treasurer Edgemond James sold 1,961 shares in an open-market transaction disclosed via Form 4.
Likely limited immediate price impact; any effect would be sentiment-driven and short-lived.
The filing specifies an open-market sale and a pre-arranged Rule 10b5-1 plan, reducing the likelihood of new, non-public information.
Market effects
Minimal; this is company-specific insider transaction with no stated operational/regulatory/drug-trial change.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with investor skepticism; traders may still fade strength if flows are heavy.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider transaction disclosure.
- insiderEdgemond James
CFO and treasurer who sold shares.
